Urovant sciences ltd. (UROV)
Income statement / Quarterly
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Dec'17Sep'17
Operating expenses:
Research and development

23,099

17,796

22,014

22,270

21,299

20,664

27,965

8,046

4,751

General and administrative

16,687

7,435

5,465

6,555

4,862

3,664

3,504

1,389

219

Total operating expenses

39,786

25,231

27,479

28,825

26,161

24,328

31,469

9,435

4,970

Other income (expense):
Interest expense, net

-1,401

-581

-513

-

-

-

-

-

-

Loss on disposal of furniture and equipment

0

0

-236

-

-

-

-

-

-

Other income (expense), net

-34

79

-190

-

-219

-309

229

6

-

Other income (expense)

-

-

-

-

-

-

-

-

59

Loss before provision for income taxes

-41,221

-25,733

-28,418

-29,042

-26,380

-24,637

-31,240

-9,429

-4,911

Provision for income taxes

38

8

67

-74

61

5

55

22

2

Net loss

-41,259

-25,741

-28,485

-28,968

-26,441

-24,642

-31,295

-9,451

-4,913

Net loss per common share—basic and diluted

-1.36

-0.85

-0.94

-0.77

-0.87

-1.23

-1.56

-0.47

-0.25

Weighted average common shares outstanding—basic and diluted

30,413

30,355

30,325

30,266

30,264

20,025

20,025

20,025

20,025